583 related articles for article (PubMed ID: 28198009)
21. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
22. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
[TBL] [Abstract][Full Text] [Related]
23. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify
Lundy J; Harris M; Zalcberg J; Zimet A; Goldstein D; Gebski V; Borsaru A; Desmond C; Swan M; Jenkins BJ; Croagh D
Front Oncol; 2021; 11():770022. PubMed ID: 34956889
[TBL] [Abstract][Full Text] [Related]
24. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
25. Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Implications from a Prospective Cohort Study.
Habib JR; Zhu Y; Yin L; Javed AA; Ding D; Tenior J; Wright M; Ali SZ; Burkhart RA; Burns W; Wolfgang CL; Shin E; Yu J; He J
J Gastrointest Surg; 2021 Dec; 25(12):3149-3159. PubMed ID: 34244950
[TBL] [Abstract][Full Text] [Related]
26. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
27. Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation.
Mansour Y; Boubaddi M; Odion T; Marty M; Belleannée G; Berger A; Subtil C; Laurent C; Dabernat S; Amintas S
Cancer Cytopathol; 2024 May; 132(5):274-284. PubMed ID: 38308613
[TBL] [Abstract][Full Text] [Related]
28. Serial EUS-Guided FNA for the Surveillance of Pancreatic Cysts: A Study of Long-Term Performance of Tumor Markers.
Rahal MA; DeWitt JM; Patel H; Schmidt CM; Ceppa EP; Simpson RE; Sherman S; Al-Haddad M
Dig Dis Sci; 2022 Nov; 67(11):5248-5255. PubMed ID: 35229208
[TBL] [Abstract][Full Text] [Related]
29. Utility of Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Preclinical Evaluation of Therapies in Cancer.
Berry W; Croagh D
Methods Mol Biol; 2018; 1725():31-40. PubMed ID: 29322406
[TBL] [Abstract][Full Text] [Related]
30. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
31. Endoscopic Ultrasound-Guided Fine-Needle Biopsies to Generate Preclinical Disease Models to Study Inflammation in Pancreatic Ductal Adenocarcinoma.
Lundy J; Croagh D
Methods Mol Biol; 2023; 2691():43-54. PubMed ID: 37355536
[TBL] [Abstract][Full Text] [Related]
32. K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma.
Sekita-Hatakeyama Y; Nishikawa T; Takeuchi M; Morita K; Takeda M; Hatakeyama K; Nakai T; Uchiyama T; Itami H; Fujii T; Mitoro A; Sho M; Ohbayashi C
PLoS One; 2018; 13(3):e0193692. PubMed ID: 29494669
[TBL] [Abstract][Full Text] [Related]
33. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
34. Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer.
Zihao G; Jie Z; Yan L; Jing Z; Jing C; Xue L; Jing Z; Heng LW; Ru G; Jianyu H
J Clin Gastroenterol; 2013 Jan; 47(1):69-75. PubMed ID: 22914344
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
[TBL] [Abstract][Full Text] [Related]
36. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
37. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
[TBL] [Abstract][Full Text] [Related]
38. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
[TBL] [Abstract][Full Text] [Related]
39. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
